Hydrafinil (also known as Fluorenol) is a compound discovered by the biopharmaceutical company Cephalon, in 2012, in their search for a next-generation improvement upon 2-benzhydrylsulfinylacetamide. They were looking for eugeroic compounds (wakefulness-promoting agents), of which 2-benzhydrylsulfinylacetamide is the most widely used. Of the dozens of possibly eugeroic compounds the company explored, Hydrafinil was one of only a handful that was viewed as a possible successor to this powerful wakefulness promoter.
How Hydrafinil Works
Very little is known about the mechanism of action exerted by Hydrafinil since it is such a new compound. However, because it was derived from 2-benzhydrylsulfinylacetamide there are some assumptions we can make about how is shows its eugeroic effect. While the exact mechanism of action of Hydrafinil remains elusive, we do have a working model of the interactions that lead to at least part of the eugeroic effect.
What makes Hydrafinil unique is that while it has similar activity in the brain as other extremely euphoric supplements, it has not been found to lead to addiction at anywhere near the rate of other DRIs. This is hypothesized to be because while Hydrafinil interacts with the same protein (DAT) as cocaine, it binds to it differently, having a much weaker and more selective effect.
Hydrafinil takes this concept even further binding to DAT proteins at only 1/3 the rate of hydrafinil. Interestingly, Hydrafinil enters the brain more easily than 2-benzhydrylsulfinylacetamide, so the same dose still maintained the same level of wakefulness-promoting properties, while theoretically lowering the possibility of abuse.
What does this mean for you?
While it is impossible to know how any compound will affect an individual’s unique biochemistry, if you do decide to buy Hydrafinil there are many possible advantages. A dose of Hydrafinil costs less than a cup of coffee and has a longer and more pronounced eugeroic effect. Hydrafinil can be used to treat narcolepsy and to help those who work night shifts stay alert. Additionally, many individuals who have been self-administering Hydrafinil have reported anti-depressant effects, leading some to hypothesize that there are serotonergic side effects that have so far gone unreported in the scientific literature.
Hydrafinil has also been reported to exhibit fewer side effects than any similar supplements. If you are prone to jaw tension, jitters, or other adverse reactions associated with stimulants you should consider buying Hydrafinil as an alternative.
As with other eugeroics, there are many that find Hydrafinil not only wakefulness promoting, but to also increases attentiveness in those who suffer from ADHD. This can allow for some to stop taking stronger stimulants to treat the disease like Adderall and Ritalin.
If you do decide to buy Hydrafinil there are some negatives to keep in mind. Some people report experiencing headaches which increase in severity with the dosage. These headaches are usually resolved by waiting for the effects of the Hydrafinil to wear off or by taking a nap, a particularly tricky endeavour after having just consumed a wakefulness-promoting agent.
Additionally, others have found Hydrafinil to have no eugeroic activity. This is likely dictated genetically. Research has indicated that specific mutations in the COMT gene responsible for producing a protein that metabolizes dopamine and other neurotransmitters, effectively renders the effects of it undetectable. This doesn’t seem to be constrained only to Hydrafinil with it affecting other eugeroic compounds based on user reports.
As with all very new compounds, there is inherent risk in ingesting them due to unforeseen interaction in the human body. This compound is especially prone to the risk of the unknown due to its very short existence in the literature (only 6 years at the time of this writing) and its relatively large chemical difference from its parent compound.
The dosage for Hydrafinil is widely excepted to be lower than that of 2-benzhydrylsulfinylacetamide, with most recommendations falling around 50 mg for a starting dose and titrating up until a comfortable level is reached. Most people find the most effective dose to be somewhere between 80-120 mg.
When you buy Hydrafinil, always look for trusted sources. While it is legal to buy Hydrafinil in the United States, this nootropic is not regulated by the Food and Drug Administration. So make sure that whatever supplier you choose is trustworthy and has had their product tested to make sure it is Hydrafinil and of an adequate purity. Hydrafinil is usually sold in its salt forms making it water soluble. Always weigh your dosages with an accurate scale (In this case a scale that has an error of +/- 5 mg would be adequate). Also, utilize volumetric dosing, which can further mitigate risks associated with inaccurate equipment.
If an individual is looking for a way to manage fatigue, focus for longer periods of time, and increase their levels of alertness, they may consider taking Hydrafinil. This nootropic is a mild stimulant that is less likely to produce uncomfortable side effects than similar compounds. Many users report having very positive experiences with Hydrafinil, with benefits seen in as little as 60 minutes after taking a dose.
- Dunn, D.; Hostetler, G.; Iqbal, M.; Marcy, V. R.; Lin, Y. G.; Jones, B.; Aimone, L. D.; Gruner, J.; Ator, M. A.; Bacon, E. R.; Chatterjee, S. (2012). “Wake promoting agents: Search for next generation modafinil, lessons learned: Part III”. Bioorganic & Medicinal Chemistry Letters.
- Ferraro L, Fuxe K, Tanganelli S, Tomasini MC, Rambert FA, Antonelli T (April 2002). “Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression”. Journal of Neuroscience Research.
- Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V, Prisinzano TE, Baumann MH (May 2009). “Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil”. The Journal of Pharmacology and Experimental Therapeutics.